The Role of Genomics and Proteomics: Technologies in Studying Non-alcoholic Fatty Liver Disease

Ancha Baranova, Lance Liotta, Emanuel Petricoin, Zobair M. Younossi*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

26 Scopus citations

Abstract

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are examples of complex diseases accompanied by changes in the expression of thousands of genes and a plethora of proteins encoded by these genes. Before the era of high-throughput analysis, typical translational research initiatives, aimed at defining the molecular targets for complex diseases, were performed on gene-by-gene basis. Innovative technologies, such as expression microarrays, mass spectromety, and reverse proteomics, now allow investigators to reveal complex patterns of the expression of biologically active molecules. For this reason, high-throughput approaches may be well suited for studies designed to untangle the molecular basis of the chronic liver diseases such as NAFLD.

Original languageEnglish
Pages (from-to)209-220
Number of pages12
JournalClinics in Liver Disease
Volume11
Issue number1
DOIs
StatePublished - Feb 2007
Externally publishedYes

Fingerprint

Dive into the research topics of 'The Role of Genomics and Proteomics: Technologies in Studying Non-alcoholic Fatty Liver Disease'. Together they form a unique fingerprint.

Cite this